Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated

MT Newswires Live

Feb 25, 2025

Myriad Genetics (MYGN) reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.

Analysts polled by FactSet expected $0.03.

Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.

Analysts surveyed by FactSet expected $211.6 million.

The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.

The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514063590"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514063590\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514063590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 17:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514063590","market":"sh","top_or_hot":-1,"title":"Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated","media":"MT Newswires Live","content":"<html><body><p> Myriad Genetics (MYGN) reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.</p><p>Analysts polled by FactSet expected $0.03.</p><p>Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.</p><p>Analysts surveyed by FactSet expected $211.6 million.</p><p>The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.</p><p>The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-25 17:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Myriad Genetics (MYGN) reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.</p><p>Analysts polled by FactSet expected $0.03.</p><p>Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.</p><p>Analysts surveyed by FactSet expected $211.6 million.</p><p>The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.</p><p>The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514063590","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514063590","pubTimestamp":1740475160,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Myriad Genetics  reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.Analysts polled by FactSet expected $0.03.Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.Analysts surveyed by FactSet expected $211.6 million.The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"Myriad Genetics第四季度调整后盈利下降，收入增加；重申全年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (MYGN) reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.Analysts polled by FactSet expected $0.03.Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.Analysts surveyed by FactSet expected $211.6 million.The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}